[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BE869490A - Procede de preparation de liposomes en solution aqueuse - Google Patents

Procede de preparation de liposomes en solution aqueuse

Info

Publication number
BE869490A
BE869490A BE78189678A BE189678A BE869490A BE 869490 A BE869490 A BE 869490A BE 78189678 A BE78189678 A BE 78189678A BE 189678 A BE189678 A BE 189678A BE 869490 A BE869490 A BE 869490A
Authority
BE
Belgium
Prior art keywords
aqueous solution
preparing liposomes
liposomes
preparing
aqueous
Prior art date
Application number
BE78189678A
Other languages
English (en)
Inventor
M Schneider
Original Assignee
Battelle Memorial Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Memorial Institute filed Critical Battelle Memorial Institute
Publication of BE869490A publication Critical patent/BE869490A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/924—Significant dispersive or manipulative operation or step in making or stabilizing colloid system
    • Y10S516/929—Specified combination of agitation steps, e.g. mixing to make subcombination composition followed by homogenization

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicinal Preparation (AREA)
BE78189678A 1977-08-05 1978-08-03 Procede de preparation de liposomes en solution aqueuse BE869490A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH961677A CH624011A5 (fr) 1977-08-05 1977-08-05

Publications (1)

Publication Number Publication Date
BE869490A true BE869490A (fr) 1979-02-05

Family

ID=4353843

Family Applications (1)

Application Number Title Priority Date Filing Date
BE78189678A BE869490A (fr) 1977-08-05 1978-08-03 Procede de preparation de liposomes en solution aqueuse

Country Status (20)

Country Link
US (1) US4224179A (fr)
JP (1) JPS5441279A (fr)
AU (1) AU520916B2 (fr)
BE (1) BE869490A (fr)
CA (1) CA1098410A (fr)
CH (1) CH624011A5 (fr)
DE (1) DE2834307A1 (fr)
DK (1) DK155036C (fr)
ES (1) ES472326A1 (fr)
FR (1) FR2399242A1 (fr)
GB (1) GB2001929B (fr)
HU (1) HU179672B (fr)
IE (1) IE47067B1 (fr)
IL (1) IL55154A (fr)
IT (1) IT1097928B (fr)
LU (1) LU80071A1 (fr)
NL (1) NL7808167A (fr)
SE (1) SE433169B (fr)
SU (1) SU1158031A3 (fr)
ZA (1) ZA784407B (fr)

Families Citing this family (296)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
IT1111367B (it) * 1978-11-17 1986-01-13 Serono Ist Farm Processo per la preparazione estemporanea di liposomi e liposomi cosi' ottenuti
ATE8584T1 (de) 1980-01-16 1984-08-15 Hans Georg Prof. Dr. Weder Verfahren und dialysiereinrichtung zur herstellung von bilayer-vesikeln und verwendung der bilayer-vesikel.
US4302459A (en) * 1980-03-19 1981-11-24 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives
EP0043327B1 (fr) * 1980-07-01 1984-01-18 L'oreal Procédé d'obtention de dispersions stables dans une phase aqueuse d'au moins une phase liquide non miscible à l'eau et dispersions correspondantes
EP0047480B1 (fr) * 1980-09-05 1986-02-05 Institut Armand Frappier Formation d'un immunosome préparé exclusivement d'antigènes viraux reconstitués sur une membrane artificielle
US4394372A (en) * 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
GR77320B (fr) * 1980-12-22 1984-09-11 Procter & Gamble
DE3269389D1 (en) * 1981-08-10 1986-04-03 Wellcome Found Pharmaceutical formulations containing antimony
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4416872A (en) * 1982-03-17 1983-11-22 The United States Of America As Represented By The Secretary Of The Army Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
AU564876B2 (en) * 1982-03-29 1987-08-27 Liposome Company, Inc., The Stable plurilamellar vesicles
US5441745A (en) * 1982-03-30 1995-08-15 Vestar, Inc. Method of delivering micellular particles encapsulating chemotherapeutic agents to tumors in a body
US5435989A (en) 1982-03-30 1995-07-25 Vestar, Inc. Method of targeting a specific location in a body
US4425334A (en) 1982-04-02 1984-01-10 The Regents Of The University Of California Functional oxygen transport system
US4612370A (en) * 1982-04-02 1986-09-16 The Regents Of The University Of California Lipid-saccharide reaction products
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0100964A3 (fr) * 1982-07-31 1984-06-13 Reifenrath, Rainer, Dr. Produit pharmaceutique pour le traitement et la prophylaxie d'infections, de la toux et d'affections obstructives des voies respiratoires, ainsi que son procédé de préparation
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
FR2540381B1 (fr) * 1983-02-08 1986-05-30 Dior Sa Parfums Christian Procede pour stimuler la croissance des cellules; composition cosmetique, pharmaceutique et composition complementaire pour milieu de culture cellulaire appliquant ce procede
US5387410A (en) * 1983-03-18 1995-02-07 Mallinckrodt, Inc. Method for enhancing magnetic resonance with compositions containing paramagnetic elements carried by liposomes
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5186941A (en) * 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
FR2561101B1 (fr) * 1984-03-13 1986-10-31 Paris Sud Universite Procede de preparation de liposomes et liposomes ainsi obtenus
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5231112A (en) * 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US4707453A (en) * 1985-04-05 1987-11-17 Becton Dickinson And Company Vesicle including a metal marker for use in an assay
US4698263A (en) * 1985-05-23 1987-10-06 Becton Dickinson And Company Sac having a marker linked thereto
CA1314481C (fr) * 1986-12-23 1993-03-16 Marcel B. Bally Preparation a base de lipodomes et antibiotique
US5409704A (en) * 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5041278A (en) * 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
FR2591105B1 (fr) 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
FR2597345B1 (fr) * 1986-04-22 1990-08-03 Oreal Composition cosmetique ou pharmaceutique a base d'une dispersion aqueuse de spherules lipidiques.
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
JP2760355B2 (ja) * 1986-06-16 1998-05-28 ザ リポソーム カンパニー，インコーポレイテッド 不均整誘導リポソーム
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
AU599456B2 (en) * 1986-11-28 1990-07-19 Liposome Company, Inc., The Phospholipid composition
US4783220A (en) * 1986-12-18 1988-11-08 Xerox Corporation Vesicle ink compositions
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
US4963297A (en) * 1987-12-22 1990-10-16 The Liposome Company, Inc. Spontaneous vesticulation of multilamellar liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
MX9203804A (es) * 1987-10-19 1992-07-01 Liposome Co Inc Sistemas farmaceuticos a base de tocoferol.
US5017501A (en) * 1987-11-25 1991-05-21 Abbott Laboratories Preparation of uniformly sized liposomes encapsulating an aqueous liquid
US4873035A (en) * 1987-11-25 1989-10-10 Abbott Laboratories Preparation of sized populations of liposomes
KR900000848B1 (ko) * 1987-12-30 1990-02-17 태평양화학 주식회사 리포좀을 함유한 화장료의 제조방법
US5807572A (en) * 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5013497A (en) * 1988-03-03 1991-05-07 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
CA1339034C (fr) * 1988-08-22 1997-04-01 Paul A. Tremblay Complexes de platine d'isomeres uniques d'acides neoalkyliques
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
EP0456724B1 (fr) 1989-01-27 1995-05-03 Immunolytics, Inc. Procede et composition de traitement de l'hypertrophie prostatique benigne
US5078986A (en) * 1989-02-15 1992-01-07 Mallinckrodt Medical, Inc. Method for enhancing magnetic resonance imaging using an image altering agent containing an excess of chelating agent
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5221535A (en) * 1989-11-13 1993-06-22 Nova Pharmaceutical Corporation Sustained release formulations of insect repellent
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5922304A (en) * 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US20020150539A1 (en) 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
ZA911974B (en) * 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5445813A (en) * 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20040208826A1 (en) * 1990-04-02 2004-10-21 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US7083778B2 (en) * 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
USRE39146E1 (en) 1990-04-02 2006-06-27 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US6989141B2 (en) * 1990-05-18 2006-01-24 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
IN172208B (fr) * 1990-04-02 1993-05-01 Sint Sa
US20010024638A1 (en) * 1992-11-02 2001-09-27 Michel Schneider Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof
US20030194376A1 (en) * 1990-05-18 2003-10-16 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
AU636481B2 (en) * 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
DK0555229T3 (da) * 1990-07-31 1996-08-19 Liposome Co Inc Akkumulation af aminosyrer og peptider i liposomer
ES2089226T3 (es) * 1990-09-06 1996-10-01 Johnson & Son Inc S C Procedimiento para estabilizar liposomas y composiciones que los contienen.
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5567432A (en) * 1991-08-02 1996-10-22 Lau; John R. Masking of liposomes from RES recognition
IL104084A (en) * 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
US5455044A (en) * 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
JPH08510748A (ja) * 1993-05-21 1996-11-12 ザ リポソーム カンパニー、インコーポレーテッド リポソームが誘発する生理的副作用の低減
ATE196248T1 (de) * 1993-11-16 2000-09-15 Skyepharma Inc Vesikel mit gesteuerter wirkstofffreisetzung
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
EP0682530B1 (fr) * 1993-12-15 2003-03-19 Bracco Research S.A. Melanges gazeux utiles comme agents de contraste ultrasonores
JP3591837B2 (ja) * 1994-02-17 2004-11-24 ニューヨーク・ブラッド・センター・インコーポレイテッド フィブリン膠およびリポソームを含有する生物学的生体接着剤組成物、その製造方法および使用
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US7091008B1 (en) 1994-07-01 2006-08-15 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthase genes and expression thereof in Bacillus hosts
US6951743B2 (en) 1997-10-31 2005-10-04 University Of Oklahoma Board Of Regents Hyaluronan synthase genes and expression thereof in bacillus hosts
US6455304B1 (en) * 1994-07-01 2002-09-24 The Board Of Regents Of The University Of Oklahoma Hyaluronate synthase gene and uses thereof
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5800833A (en) * 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2227013A1 (fr) 1995-07-14 1997-02-06 Glycotech Corp. Composes et methodes de traitement de cancers lies au recepteur egf et purification du recepteur egf
US6022500A (en) * 1995-09-27 2000-02-08 The United States Of America As Represented By The Secretary Of The Army Polymer encapsulation and polymer microsphere composites
US6447800B2 (en) 1996-01-18 2002-09-10 The University Of British Columbia Method of loading preformed liposomes using ethanol
US6143287A (en) * 1996-02-27 2000-11-07 New York Blood Center, Inc. Method and composition for hair removal
AU736301B2 (en) 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
ES2289188T3 (es) * 1996-09-11 2008-02-01 Bristol-Myers Squibb Medical Imaging, Inc. Procedimiento para la obtencion de imagenes para el diagnostico usando un agente de contraste y un vasodilatador.
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
EP2113247A3 (fr) 1997-05-14 2010-05-05 The University Of British Columbia Encapsulation hautement éfficace d'acides nucléiques dans des vésicules lipidiques
DE69841002D1 (de) * 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
WO1999002139A1 (fr) * 1997-07-10 1999-01-21 Keith Baker Procedes permettant d'alimenter le cerveau en agents therapeutiques de façon universelle
US6306432B1 (en) 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
WO1999013865A1 (fr) 1997-09-18 1999-03-25 Depotech Corporation Compositions anesthesiques de liposomes a liberation prolongee
EP1025211B1 (fr) * 1997-10-31 2004-12-15 The Board of Regents of The University of Oklahoma Gene de la synthase de l'hyaluronan et utilisation de ce gene
CN101113436B (zh) * 1997-10-31 2013-02-06 俄克拉何马大学董事会 透明质酸合酶基因及其应用
WO1999025319A1 (fr) 1997-11-14 1999-05-27 Depotech Corporation Production de liposomes multivesiculaires
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6727079B1 (en) * 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
US20080108110A1 (en) * 1998-04-02 2008-05-08 Deangelis Paul L Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US6987023B2 (en) * 1998-04-02 2006-01-17 The Board Of Regents Of The University Of Oklahoma DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
US7223571B2 (en) * 1998-04-02 2007-05-29 The Board Of Regents Of The Universtiy Of Oklahoma Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US20060188966A1 (en) * 1998-04-02 2006-08-24 Deangelis Paul L Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same
US7169410B1 (en) * 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
US7094581B2 (en) * 1998-10-26 2006-08-22 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthases and methods of making and using same
ATE343562T1 (de) 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US20050287638A1 (en) * 2000-04-25 2005-12-29 Weigel Paul H Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
WO2002002506A2 (fr) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Composes pour traiter la maladie d'alzheimer
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
PL363618A1 (en) * 2000-11-09 2004-11-29 Neopharm, Inc. Sn-38 lipid complexes and methods of use
US20110301569A1 (en) 2001-01-20 2011-12-08 Gordon Wayne Dyer Methods and apparatus for the CVCS
AU2002258603A1 (en) * 2001-03-23 2002-10-15 University Of Michigan Method of inhibiting cancerous cell proliferation using ras mutants of gdp-bound conformation
WO2003030864A1 (fr) * 2001-05-29 2003-04-17 Neopharm, Inc. Formulation liposomale d'irinotecan
WO2003002122A1 (fr) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Derives de beta-hydroxyamine utiles dans le traitement de la maladie d'alzheimer
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
EP1441763A2 (fr) * 2001-11-07 2004-08-04 Inex Pharmaceuticals Corp. Modeles ameliores de vaccins administrables par voie muqueuse et modes d'utilisation
US7476400B2 (en) * 2001-11-13 2009-01-13 Ferndale Ip, Inc. High-concentration lidocaine compositions and methods for their preparation
US20070020737A1 (en) * 2001-12-03 2007-01-25 Pummill Philip E Hyaluronan synthases and methods of making and using same
US20030134423A1 (en) * 2002-01-04 2003-07-17 Chu Yong Liang Compounds for delivering substances into cells
WO2003059280A2 (fr) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Encapsulation efficace dans un liposome
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
AU2003304204B2 (en) 2002-10-29 2009-12-24 Insmed Incorporated Sustained release of antiinfectives
CN100377704C (zh) * 2002-11-26 2008-04-02 吉里德科学公司 脂质体制剂
US6866856B2 (en) * 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
EP1695696A1 (fr) * 2003-12-01 2006-08-30 Mitsubishi Pharma Corporation Liposome
US7504385B2 (en) * 2003-12-17 2009-03-17 Avon Products, Inc. si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
US8022279B2 (en) 2004-04-22 2011-09-20 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
WO2006014626A2 (fr) 2004-07-19 2006-02-09 Celator Pharmaceuticals, Inc. Produits de synthese particulaires destines a la liberation d'agents actifs
EP1807051A2 (fr) 2004-11-05 2007-07-18 Inex Pharmaceuticals Corporation Compositions et methodes destinees a stabiliser des preparations medicamenteuses liposomales
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2
US7459529B2 (en) 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
AU2005318928B2 (en) * 2004-12-20 2010-06-03 Australian Nuclear Science & Technology Organisation Controlled release of biological entities
EP1838289B1 (fr) * 2004-12-20 2017-12-13 Australian Nuclear Science And Technology Organisation Liberation controlee d'entites biologiques
AU2006257727B2 (en) * 2005-06-17 2010-09-09 Encap Hive Pty Ltd Particles comprising a releasable dopant therein
BRPI0611886B8 (pt) * 2005-06-17 2021-05-25 Australian Nuclear Science & Tech Organisation partículas que compreendem um dopante hidrofóbico e seu processo para fabricação e método para distribuir um dopante hidrofóbico
US9345667B2 (en) 2005-06-17 2016-05-24 Australian Nuclear Science And Technology Organisation Particles having hydrophobic material therein
AU2006257726B2 (en) * 2005-06-17 2010-09-09 Australian Nuclear Science And Technology Organisation Particles having hydrophobic material therein
WO2007032225A1 (fr) * 2005-09-15 2007-03-22 Kyoto University Liposome, procede de fabrication d’un liposome et procede de controle d’une reaction dans un espace de microreaction
EP1948674A4 (fr) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Molecules d'arnsi modifiees et utilisations de celles-ci
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9149543B2 (en) * 2005-12-15 2015-10-06 The Trustees Of The University Of Pennsylvania Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors
US20080094573A1 (en) * 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
EP2752423A3 (fr) * 2006-09-18 2015-02-18 Compugen Ltd. Ligands du GPCR et procédé pour leur utilisation
AU2007351891A1 (en) 2006-10-03 2008-10-30 The Board Of Regents Of The University Of Oklahoma Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
EP2155165A1 (fr) * 2007-04-20 2010-02-24 BioCure, Inc. Véhicule pour l'administration de médicaments contenant des vésicules dans une base hydrogel
EP2167534B1 (fr) 2007-07-12 2012-07-04 Compugen Ltd. Peptides bioactifs et leur procede d'utilisation
ITRM20070394A1 (it) * 2007-07-16 2009-01-17 Uni Cattolica Del Sacro Cuo Re Liposomi asimmetrici e loro usi in campo medico.
EP2187869B1 (fr) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Préparations améliorées de médicaments au platine
EP3156077B1 (fr) 2007-12-04 2022-03-09 Arbutus Biopharma Corporation Lipides de ciblage
EP2231190B1 (fr) * 2007-12-06 2012-09-26 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Vecteurs de médicaments particulaires en tant qu'agents de désensibilisation
EP2229583B1 (fr) 2007-12-06 2019-04-10 Genalyte Inc. Système et procédé de surveillance de synthèse d'acide nucléique sans marqueurs
CA2710713C (fr) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencage de l'expression de la polo-like kinase a l'aide d'un arn interferent
EP3100718B1 (fr) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Compositions améliorées et procédés d'administration d'acides nucléiques
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
CA2721380A1 (fr) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Reduction au silence de l'expression du gene csn5 au moyen d'arn interferant
CN102149398B (zh) 2008-09-11 2013-12-04 I·B·R·以色列生物科技研究有限公司 雪片莲属鳞茎提取物及其用途
PL2350043T3 (pl) 2008-10-09 2014-09-30 Tekmira Pharmaceuticals Corp Ulepszone aminolipidy i sposoby dostarczania kwasów nukleinowych
JP5656853B2 (ja) 2008-10-27 2015-01-21 ジェナリーテ， インコーポレイテッド 光学的な探査及び検知に基づくバイオセンサ
WO2010054405A1 (fr) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Nouveaux lipides et nouvelles compositions pour l’administration d’agents thérapeutiques
CA2751342C (fr) 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Formules lipides renfermant un lipide cationique et un lipide cible renfermant de la galactosamine n-acetyle pour la livraison d'acide nucleique
EP2395977A2 (fr) 2009-02-11 2011-12-21 Lyka Labs Limited Injection liposomale de citicoline
JP6032724B2 (ja) 2009-03-12 2016-11-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 脂質製剤組成物およびＥｇ５遺伝子とＶＥＧＦ遺伝子の発現を阻害する方法
JP5487666B2 (ja) * 2009-03-23 2014-05-07 コニカミノルタ株式会社 内水相を固定化することを特徴とするリポソームの製造方法
WO2010129687A1 (fr) 2009-05-05 2010-11-11 Alnylam Pharmaceuticals, Inc Procédés d'administration d'oligonucléotides en direction de cellules immunitaires
CA3151387A1 (fr) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Compositions de lipides servant a distribuer des agents therapeutiques
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
WO2011011447A1 (fr) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions et méthodes pour rendre silencieuse l’expression du gène du virus ebola
FR2948035B1 (fr) * 2009-07-20 2015-04-24 Centre Nat Rech Scient Procede de fabrication de capsules, capsules ainsi obtenues et utilisation desdites capsules
EP2464336A4 (fr) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc Compositions formulées dans des lipides et procédés pour inhiber l' expression d'un gène du virus ebola
EP2480668A2 (fr) 2009-09-23 2012-08-01 Protiva Biotherapeutics Inc. Compositions et procédés pour réduire au silence des gènes exprimés dans le cancer
WO2011056682A1 (fr) 2009-10-27 2011-05-12 The University Of British Columbia Lipides à têtes polaires inversées, compositions particulaires lipidiques comprenant les lipides à têtes polaires inversées, et procédés d'administration d'acides nucléiques
WO2011071860A2 (fr) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions utilisées pour l'administration d'acides nucléiques
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
CA2800401C (fr) 2010-06-03 2020-09-15 Alnylam Pharmaceuticals, Inc. Lipides biodegradables pour l'administration de principes actifs
WO2012016188A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour l'administration d'agents actifs
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
CA2816995C (fr) 2010-11-05 2019-12-31 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, a body corporate and politic Systemes optiques de detection d'analytes et leurs procedes d'utilisation
US8518871B2 (en) 2010-11-09 2013-08-27 The Regents Of The University Of California Skin permeating and cell entering (SPACE) peptides and methods of use thereof
WO2012099755A1 (fr) 2011-01-11 2012-07-26 Alnylam Pharmaceuticals, Inc. Lipides pégylés et leur utilisation pour une administration de médicament
EP2907504B1 (fr) 2011-02-08 2017-06-28 Halozyme, Inc. Composition et formulation de lipides d'une enzyme de dégradation d'hyaluronan et leur utilisation pour le traitement de l'hyperplasie bénigne de la prostate
WO2013004234A2 (fr) 2011-07-04 2013-01-10 Statens Serum Institut Procédé de production de liposomes
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
US20150240238A1 (en) 2011-11-17 2015-08-27 The Regents Of The University Of California Therapeutic rna switches compositions and methods of use
EP2606897A1 (fr) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Procédés et compositions pour le traitement des maladies causées par les virus enveloppés
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
US9352042B2 (en) 2012-02-24 2016-05-31 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
WO2013138251A1 (fr) 2012-03-12 2013-09-19 The Board Of Trustes Of The University Of Illinois Systèmes optiques de détection d'analyte avec amplification magnétique et procédés d'utilisation
EP2666456A1 (fr) 2012-05-21 2013-11-27 Natura Bisse International, S.A. Compositions cosmétiques comprenant des magnetosomes et utilisations associées
DK2892524T3 (da) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC Forebyggelse af pulmonalt kræfttilbagefald med lipid-komplekseret cisplatin
EP3033325B1 (fr) 2013-07-23 2019-12-04 Arbutus Biopharma Corporation Compositions et procédés pour l'administration d'arn messager
KR101465365B1 (ko) * 2013-10-15 2014-11-25 성균관대학교산학협력단 리포좀 내 고분자 충진된 다중 기능 복합 입자체 및 이의 제조방법
KR101638156B1 (ko) 2013-10-29 2016-07-08 가톨릭대학교 산학협력단 C형 간염 바이러스 감염 질환의 예방 또는 치료용 약학 조성물
EP3186281B1 (fr) 2014-08-28 2019-04-10 Halozyme, Inc. Thérapie combinée associant une enzyme dégradant le hyaluronane et un inhibiteur des postes de contrôle immunitaire
CA2963271A1 (fr) 2014-10-02 2016-04-07 Protiva Biotherapeutics, Inc. Compositions et methodes d'extinction de l'expression du gene du virus de l'hepatite b
US20170369872A1 (en) 2014-12-18 2017-12-28 Alnylam Pharmaceuticals, Inc. Reversir tm compounds
JP6316182B2 (ja) 2014-12-19 2018-04-25 富士フイルム株式会社 リポソームの製造方法及びリポソーム製造装置
EP4154915A1 (fr) 2014-12-31 2023-03-29 Lantheus Medical Imaging, Inc. Compositions de microsphères gazeuses enrobées de lipides et procédés connexes
CA3024951A1 (fr) 2015-05-26 2016-12-01 Comfort Care For Animals Llc Chargement de liposome
WO2016197132A1 (fr) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Traitement d'une infection à virus de l'hépatite b à de l'aide de crispr
EP3329003A2 (fr) 2015-07-29 2018-06-06 Arbutus Biopharma Corporation Compositions et méthodes de silençage de l'expression du gène du virus de l'hépatite b
US10429302B2 (en) 2015-08-11 2019-10-01 Scintillon Institute For Biomedical And Bioenergy Research Optical analyses of particles and vesicles
US10363226B2 (en) 2015-08-12 2019-07-30 North Carolina State University Platelet membrane-coated drug delivery system
EP3399966B1 (fr) 2016-01-08 2023-03-29 The Regents of the University of California Nanoparticules de silice mésoporeuse à revêtement à bicouche lipidique pour l'administration d'une charge
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201807593TA (en) 2016-04-14 2018-10-30 Hutchinson Fred Cancer Res Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
MX2018013409A (es) 2016-05-04 2019-07-08 Lantheus Medical Imaging Inc Métodos y dispositivos para la preparación de agentes de contraste de ultrasonido.
AU2017286980B2 (en) 2016-06-30 2023-10-26 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
EP4371584A3 (fr) 2016-12-21 2024-08-28 Fred Hutchinson Cancer Center Échafaudages pour traiter des cellules tumorales solides et des variantes d'échappement
US11566061B2 (en) 2017-01-05 2023-01-31 Fred Hutchinson Cancer Center Systems and methods to improve vaccine efficacy
TW201936201A (zh) 2017-12-14 2019-09-16 美商堅固生物科技公司 基因之非病毒生產及遞送
MA56536A (fr) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Co Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb)
US20210023023A1 (en) * 2019-07-25 2021-01-28 Vasayo, Llc Liposomal nutraceutical compositions and methods of making the same
KR20220154740A (ko) 2020-03-17 2022-11-22 제네반트 사이언시즈 게엠베하 간 성상 세포로 치료제의 지질 나노입자 전달을 위한 양이온성 지질
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2022212863A1 (fr) 2021-04-01 2022-10-06 Vestaron Corporation Formulations de liposomes destinées à l'administration de pesticides et leurs procédés de production et d'utilisation
WO2023018990A2 (fr) 2021-08-12 2023-02-16 Life Technologies Corporation Lipides pour l'administration d'acides nucléiques
AU2023214198A1 (en) 2022-01-31 2024-08-15 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles
AU2023211981A1 (en) 2022-01-31 2024-08-15 Genevant Sciences Gmbh Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
WO2023233290A1 (fr) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Agents d'arni ciblant pd-l1
NL2035417B9 (en) 2022-07-19 2024-10-09 Coty Inc Cosmetic composition
WO2024031051A1 (fr) 2022-08-05 2024-02-08 Life Technologies Corporation Lipides pour l'administration d'acides nucléiques
WO2024168010A2 (fr) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Molécules de reversir et leurs procédés d'utilisation
WO2024209267A2 (fr) 2023-04-03 2024-10-10 Jazz Pharmaceuticals Ireland Limited Modulateurs de l'absorption de nanoparticules

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361680A (en) * 1963-05-13 1968-01-02 Sun Oil Co Use of ultrasonic vibrations to disperse a liquid in another liquid
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
DE2249552A1 (de) * 1971-10-12 1973-05-30 Inchema S A Verfahren zur inkapsulation von insbesondere wasserloeslichen verbindungen
US3932657A (en) * 1973-11-12 1976-01-13 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome encapsulation of chelating agents
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
CH588887A5 (fr) * 1974-07-19 1977-06-15 Battelle Memorial Institute
JPS5126213A (ja) * 1974-08-21 1976-03-04 Tanabe Seiyaku Co Johoseibiryushiseizaino seiho
FR2315991A1 (fr) * 1975-06-30 1977-01-28 Oreal Procede de fabrication de dispersions aqueuses de spherules lipidiques et nouvelles compositions correspondantes
IL51791A0 (en) * 1976-04-14 1977-05-31 Exxon Research Engineering Co New injectable medicinal compositions
JPS5323872A (en) * 1976-08-17 1978-03-04 Takeda Chem Ind Ltd Preparation of microcapsule
US4107106A (en) * 1976-11-22 1978-08-15 Union Carbide Corporation Phenol-aldehyde-amine resin/glycol curatives for energy absorbing polyurethanes
ATE159658T1 (de) * 1989-09-05 1997-11-15 Univ Utah Research Inst Verfahren und zusammensetzungen zur verabreichung von lipophilen heilmitteln in einer dosierung nach der gewünschten wirkung

Also Published As

Publication number Publication date
CH624011A5 (fr) 1981-07-15
DK155036B (da) 1989-01-30
JPS5441279A (en) 1979-04-02
DE2834307A1 (de) 1979-02-15
JPS6355978B2 (fr) 1988-11-07
FR2399242A1 (fr) 1979-03-02
IL55154A (en) 1981-09-13
CA1098410A (fr) 1981-03-31
IL55154A0 (en) 1978-09-29
IE781574L (en) 1979-02-05
ES472326A1 (es) 1979-02-16
NL7808167A (nl) 1979-02-07
SE433169B (sv) 1984-05-14
IT7826441A0 (it) 1978-08-03
HU179672B (en) 1982-11-29
SE7808356L (sv) 1979-02-06
ZA784407B (en) 1979-07-25
FR2399242B1 (fr) 1983-01-07
AU3866678A (en) 1980-02-07
IT1097928B (it) 1985-08-31
US4224179A (en) 1980-09-23
SU1158031A3 (ru) 1985-05-23
DK155036C (da) 1989-06-26
GB2001929B (en) 1982-07-28
DK344478A (da) 1979-02-06
IE47067B1 (en) 1983-12-14
AU520916B2 (en) 1982-03-04
GB2001929A (en) 1979-02-14
LU80071A1 (fr) 1979-05-15

Similar Documents

Publication Publication Date Title
LU80071A1 (fr) Procede de preparation de liposomes en solution aqueuse
BE863883A (fr) Procede de preparation de derives de la pyrrolidine
FR2323705A1 (fr) Procede de preparation de solutions aqueuses de polyvinylpyrrolidone-iode
BE858771A (fr) Procede de preparation de bitumes-polymeres
BE865808A (fr) Procede de preparation de l'ethylene-glycol
BE870162A (fr) Procede de preparation de p-benzoquinonediacetals
BE855944A (fr) Procede de preparation des 1-phenyl-3-amino-pyrazoles
FR2345434A1 (fr) Procede de preparation de la 5-acetoacetylamino-benzimidazolone
LU81064A1 (fr) Procede de preparation de trifluoromethylphenols
BE848143A (fr) Procede de preparation de l'acide cis-2-hydroxy-2-phenyl-r-1-cyclohexanecarboxylique,
BE858628A (fr) Procede de preparation de l'ethylene-glycol
BE839004A (fr) Procede de preparation de 4-oxo-hexahydropyrazino-isoquinoleine
PT68138A (fr) Procede de preparation de methoxy-2 benzamides
BE863284A (fr) Procede de preparation de derives de cholesterol
BE872842A (fr) Procede de preparation de derives de 1-hydroxyaporphine
BE874713A (fr) Procede de preparation de p-amino-diphenylamine
BE861501A (fr) Procede de preparation de la 17alpha-hydroxy-21-acetoxy-progesterone
BE856410A (fr) Procede de preparation de cis-hexahydrodibenzopyranones
BE872383A (fr) Procede de preparation de phenylbutenones
BE872139A (fr) Procede de preparation de l'acide d,1-betabenzoylamino-iso-butyrique
MA18501A1 (fr) Procede de preparation de sulfonyl-urees
BE859998A (fr) Procede de preparation de dihalogenures dioganostanniques
BE870978A (fr) Procede de preparation de la (-)-vincamine
BE837753A (fr) Procede de preparation de sulfonylurees
BE863017A (fr) Procede de preparation de n-alkylcarbamates

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: BATTELLE MEMORIAL INSTITUTE

Effective date: 19900831